Nuvalent CFO exercised 20,000 options, sold 20,000 shares Oct 1 2025
Rhea-AI Filing Summary
Alexandra Balcom, Chief Financial Officer of Nuvalent, Inc. (NUVL), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 trading plan adopted on 12/12/2024. The filing shows purchases (option exercises) totaling 20,000 shares acquired at exercise prices of $6.89 and $18.93, and open stock option holdings of 20,000 underlying shares exercisable through 2031 and 2032. Balcom sold 20,000 Class A shares in two weighted-average-price blocks: 19,030 shares at an average of $85.43 and 970 shares at an average of $86.37, leaving 61,734 Class A shares beneficially owned after the transactions. The filing was signed by an attorney-in-fact on 10/03/2025.
Positive
- Rule 10b5-1 trading plan was used, indicating preplanned transactions adopted on 12/12/2024
- Options exercised to acquire 20,000 shares at low exercise prices ($6.89 and $18.93), increasing vested equity
- Significant retained stake remains: 61,734 Class A shares beneficially owned after sales
Negative
- Sales of 20,000 Class A shares reduced holdings and were executed at high market prices (weighted averages $85.43 and $86.37)
- Material dispositions (total sales equal to ~24% of pre-transaction reported beneficial ownership of 78,521 shares) — disclosed by reported amounts
Insights
Insider sold 20,000 shares under a Rule 10b5-1 plan on 10/01/2025.
The filing documents sales of 19,030 shares at a weighted average price of $85.43 and 970 shares at $86.37, executed under a preexisting Rule 10b5-1 plan adopted on 12/12/2024. The reporter also exercised options to acquire 20,000 shares at exercise prices of $6.89 and $18.93, increasing vested equity before the sales.
These are routine, preplanned transactions; the use of a 10b5-1 plan indicates the trades were scheduled in advance, which is relevant when assessing potential information asymmetry.
Post-transaction beneficial ownership stands at 61,734 Class A shares.
The filing shows the CFO retains substantial ownership—61,734 Class A shares—after exercising options and selling shares. Option vesting schedules disclosed confirm some options remain subject to standard time-based vesting through 2032. The signature by an attorney-in-fact on 10/03/2025 is noted.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 16,787 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 3,213 | $0.00 | -- |
| Exercise | Class A Common Stock | 16,787 | $6.89 | $116K |
| Exercise | Class A Common Stock | 3,213 | $18.93 | $61K |
| Sale | Class A Common Stock | 19,030 | $85.43 | $1.63M |
| Sale | Class A Common Stock | 970 | $86.37 | $84K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.99, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.07 to $86.52, inclusive. The shares underlying this option vest as follows: 25% of the shares vested on April 29, 2022, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
